hip arthroplasty patients
recovery of hip fracture patients
hip fracture arthroplasty
PLX-PAD
Hip fractures
stratifying patients
elderly patients
injured patients
cell therapy
main medical problems of hip fracture
multicenter phase
clinical trial
effect of PLX
trial Aim
innovative therapy
clinical study
placebo controlled phase
stromal cell product
in-depth biomarker studies of treated patients
functional recovery
Advanced Therapy Medicinal Product
patient organisations
patient experience
efficacy of intraoperative intramuscular injections of PLX
individual stress reactions
adherent stromal cells
strategic patient engagement
muscle force
muscle regeneration
high mortality
HIPGEN project
main organisation
reduction of early postoperative stress
preclinical characterisation
future therapies
Conventional therapies
combined result of injury
comprehensive preclinical work
survival
biomechanical analyses
EU
major public health concern
indirect costs
year
consortium
volume
immunology
immune system
double blind
mechanisms of action
renown experts
Charit√©
increase
effects
ATMP
surgery
osteoporosis
increasing incidence
addition
clinicians
collaboration of Pluristem
impairment of mobility
IOF
immobilisation
Placenta
platform
results
Partner
indication